Biotechnology News and Research

RSS

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BioTime, Inc. and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

28 Jan 2014

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections.

27 Jan 2014

Researchers find novel drug combination approach to speed fight against cancer

Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way.

27 Jan 2014

New innovations in booming 3D printing industry

As global demand for new innovations in the booming 3D printing industry grows exponentially by the day, Rainbow Coral Corp. (OTCBB: RBCC) is preparing to capitalize with groundbreaking new products for the 3D marketplace.

27 Jan 2014

New method allows for large-scale generation of human embryonic stem cells

A new method allows for large-scale generation of human embryonic stem cells of high clinical quality. It also allows for production of such cells without destroying any human embryos.

27 Jan 2014

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

ITAC assists in international distribution of NanoLogix products by Nasaem Al-Jazira

NanoLogix Inc. (NNLX), an innovator in the rapid detection, identification and determination of antibiotic resistance and sensitivity of live bacteria, announces that the State of Ohio Department of Economic Development's International Trade Assistance Center (ITAC) based at Youngstown State University (YSU) is providing support to Hubbard Ohio-based NanoLogix Inc. for international distribution of NanoLogix products by Nasaem Al-Jazira, a Saudi Arabian Trading and Distribution Company.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

UM professors receive grant to help athletes, military members suffering from traumatic brain injury

Athletes, members of the military and others suffering from traumatic brain injury may benefit from research conducted by two University of Montana faculty members through a new $300,000 grant awarded by General Electric Co. and the National Football League.

25 Jan 2014

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

e-Therapeutics plc today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials.

24 Jan 2014

FDA mandates enrollment and monitoring of women in post-approval studies for medical devices

The U.S. Food and Drug Administration (FDA) mandates adequate enrollment of women in post-approval studies (PAS) of medical devices to ensure that any sex differences in device safety and effectiveness are not overlooked.

24 Jan 2014

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

The National Institutes of Health has awarded Benaroya Research Institute at Virginia Mason a 7-year grant to lead the Immune Tolerance Network.

24 Jan 2014

'Smart' holograms could be used to monitor diabetes, cardiac function, infections

Responsive holograms that change colour in the presence of certain compounds are being developed into portable medical tests and devices, which could be used to monitor conditions such as diabetes, cardiac function, infections, electrolyte or hormone imbalance easily and inexpensively.

23 Jan 2014

Rice University-based research develops fast biosensor for pathogens in food

An array of tiny diving boards can perform the Olympian feat of identifying many strains of salmonella at once.

23 Jan 2014

Researchers discover new gene involved in severe childhood epilepsy

A European consortium of epilepsy researchers has reported the discovery of a new gene involved in severe childhood epilepsy. Using a novel combination of technologies, including trio exome sequencing of patient/parental DNA and genetic studies in the tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found that mutations in the gene CHD2 are responsible for a subset of epilepsy patients with symptoms similar to Dravet syndrome - a severe form of childhood epilepsy that is in many patients resistant to currently available anti-epileptic drugs.

23 Jan 2014

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Patrys Limited, a clinical stage biotechnology company is pleased to announce the publication of a new scientific article regarding its product PAT-SC1 in the Oncology Reports journal. The article is currently available online and will be included in a future print edition of the journal.

22 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.

21 Jan 2014

Trendlines Labs signs deal for collaboration with Roper St. Francis Healthcare

Trendlines Labs (a unit of the Trendlines Group) recently signed an agreement for collaboration with Roper St. Francis Healthcare.

21 Jan 2014

Biotechnology News and Research

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Researchers find novel drug combination approach to speed fight against cancer

New innovations in booming 3D printing industry

New method allows for large-scale generation of human embryonic stem cells

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

ITAC assists in international distribution of NanoLogix products by Nasaem Al-Jazira

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

UM professors receive grant to help athletes, military members suffering from traumatic brain injury

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

FDA mandates enrollment and monitoring of women in post-approval studies for medical devices

BRI receives grant to lead ITN for evaluating novel therapies for transplantation, allergy and autoimmune diseases

'Smart' holograms could be used to monitor diabetes, cardiac function, infections

Rice University-based research develops fast biosensor for pathogens in food

Researchers discover new gene involved in severe childhood epilepsy

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

Trendlines Labs signs deal for collaboration with Roper St. Francis Healthcare

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News